Prof. Chong-Xian Pan
Harvard Medical School, USA
Associate Professor
Email: Chongxian_pan@hms.harvard.edu
Qualifications
2007 Ph.D., University of California at Davis,
USA
1999 Ph.D., Loyola University Chicago,
USA
1989 M.Sc., Fudan University,
China
Publications (Selected)
-
Miao, H., Fang, Y., Pan, C., Yang, H., Wang, Z., Qi, Y., ... & Li, N. (2025). Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives. Medicine Plus, 100087.
-
Barata, P. C., Corrigan, J., Culnan, J., Dulberger, K. N., La, J., Akama-Garren, E., ... & PROFOUND-VET Investigators Group. (2025). Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).
-
White, B. S., Woo, X. Y., Koc, S., Sheridan, T., Neuhauser, S. B., Wang, S., ... & Chuang, J. H. (2024). A pan-cancer patient-derived xenograft histology image repository with genomic and pathologic annotations enables deep learning analysis. Cancer research, 84(13), 2060-2072.
-
Abd El‐Salam, M. A., Troulis, M. J., Pan, C. X., & Rao, R. A. (2024). Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques. Cancer Cytopathology, 132(2), 96-102.
-
Xue, X., Qu, H., Bo, R., Zhang, D., Zhu, Z., Xiang, B., ... & Li, Y. (2023). A transformable nanoplatform with multiple therapeutic and immunostimulatory properties for treatment of advanced cancers. Biomaterials, 299, 122145.
-
Steele, T. M., Tsamouri, M. M., Siddiqui, S., Lucchesi, C. A., Vasilatis, D., Mooso, B. A., ... & Ghosh, P. M. (2023). Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. Scientific reports, 13(1), 9617.
-
Farrukh, H., Zhu, Z., Zhu, S., Montgomery, R. B., Meeks, J. J., VanderWeele, D. J., ... & Pan, C. X. (2023). A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy.
-
Farrukh, H., Zhu, Z., Garisto Risco, J., Lam, K. S., & Pan, C. X. (2023). A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
-
Ma, W., Xue, R., Zhu, Z., Farrukh, H., Song, W., Li, T., ... & Pan, C. X. (2023). Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental hematology & oncology, 12(1), 10.
-
Zhu, Z., Ma, A. H., Zhang, H., Lin, T. Y., Xue, X., Farrukh, H., ... & Pan, C. X. (2022). Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer. Clinical Cancer Research, 28(21), 4820-4831.
-
Abd El‐Salam, M. A., Smith, C. E., & Pan, C. X. (2022). Insights on recent innovations in bladder cancer immunotherapy. Cancer cytopathology, 130(9), 667-683.
-
Rehman, H., Chandrashekar, D. S., Balabhadrapatruni, C., Nepal, S., Balasubramanya, S. A. H., Shelton, A. K., ... & Ferguson III, J. E. (2022). ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI insight, 7(16), e155899.
-
Koc, S., Lloyd, M. W., Grover, J. W., Xiao, N., Seepo, S., Subramanian, S. L., ... & Chuang, J. H. (2022). PDXNet portal: patient-derived xenograft model, data, workflow and tool discovery. NAR cancer, 4(2), zcac014.
-
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C. X., & Zhu, Z. (2022). CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of experimental & clinical cancer research, 41(1), 119.
-
Bekele, R. T., Samant, A. S., Nassar, A. H., So, J., Garcia, E. P., Curran, C. R., ... & Mouw, K. W. (2021). RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. The Journal of Clinical Investigation, 131(22).
Profile Details
https://connects.catalyst.harvard.edu/Profiles/display/Person/186514
https://www.linkedin.com/in/chong-xian-pan-32625a200/
https://scholar.google.com/citations?user=Tz-QaYMAAAAJ&hl=en